Part II: Current Treatment Options for Neurogenic Bladder Dysfunction
Release Date: July 2012
Expiration Date: July 2013
Estimated time to complete the educational activity: 1 hour
This activity is jointly sponsored by Medical Education Resources and Haymarket Medical Education and is supported by an educational grant from Allergan, Inc.
Statement of Need: Urologists and other healthcare professionals caring for patients with neurogenic bladder (NGB) dysfunction need to be knowledgeable about the various treatment options for NGB, including options for patients who fail behavioral or oral therapy, to provide optimal therapy. Since successful treatment encompasses patient satisfaction as well as meaningful improvement in symptoms, clinicians need to be aware of the impact of patient considerations and satisfaction in the management of NGB dysfunction.
Target Audience: This activity has been designed to meet the educational needs of urologists and other clinicians involved in the treatment of patients with bladder dysfunction.
Educational Objectives: After completing the activity, the participant should be better able to:
- Evaluate management options for neurogenic bladder dysfunction, including evidence-based treatments and novel therapeutic approaches
- Explain the impact of patient considerations and satisfaction in the management of neurogenic bladder dysfunction
Accreditation Statement:This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Haymarket Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: Medical Education Resources designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest: Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality CME activities that promote improvements or quality in health care and not a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:
|Name of Faculty||Reported Financial Relationship|
|Michael B. Chancellor, MD||Grants/Research Support: Allergan, Inc., Medtronic, Inc., Pfizer Inc.
Consultant: Astellas, Allergan, Inc., Cook MyoSite, Inc., Lipella Pharmaceuticals, Inc., Pfizer Inc.
Ownership: Lipella Pharmaceuticals, Inc.
Royalty/Patent Holder: Cook MyoSite, Inc., Lipella Pharmaceuticals, Inc.
The content managers, Debra A. Hughes, Mary Jo Krey, Lori Marrese, Jody A. Charnow, and Marina Galanakis of Haymarket Medical Education, and Victoria Smith, MD, of Medical Education Resources, have disclosed that they have no relevant financial relationships or conflicts of interest.
Method of Participation: There are no fees for participating in and receiving CME credit for this activity. During the period July 2012 through July 2013, participants must: 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest and submit it online. Physicians may register at www.myCME.com/renalandurologynews, and 4) complete the evaluation form online.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.